A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

2023-506247-42-00 Protocol R5458-ONC-2012 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 17 Aug 2022 · Status Ongoing, recruiting · 4 EU/EEA countries · 27 sites · Protocol R5458-ONC-2012

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 385
Countries 4
Sites 27

Relapsed/Refractory Multiple Myeloma

Key facts

Sponsor
Regeneron Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
17 Aug 2022 → ongoing
Decision date (initial)
2024-07-02
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2023-506247-42-00
EudraCT number
2020-004638-39
ClinicalTrials.gov
NCT05137054

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed/Refractory Multiple Myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Regeneron Pharmaceuticals Inc.

Sponsor organisation
Regeneron Pharmaceuticals Inc.
Address
777 Old Saw Mill River Road
City
Tarrytown
Postcode
10591-6717
Country
United States

Scientific contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Medical Affairs

Public contact point

Organisation
Regeneron Pharmaceuticals Inc.
Contact name
Medical Affairs

Locations

4 EU/EEA countries · 27 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 88 10
Greece Ongoing, recruiting 70 2
Netherlands Authorised, recruitment pending 40 2
Spain Ongoing, recruiting 111 13
Rest of world
Israel, United States
76

Investigational sites

France

10 sites · Ongoing, recruiting
Centre Hospitalier Universitaire De Poitiers
Service d’hématologie et Thérapie Cellulaire Pôle Régional de Cancérologie, 2 Rue De La Miletrie, 86000, Poitiers
Centre Hospitalier Universitaire D'Angers
Service Maladies du Sang, 4 Rue Larrey, 49100, Angers
Centre Hospitalier Universitaire De Montpellier
Hematologie clinique, 80 Avenue Augustin Fliche, 34295, Montpellier Cedex 5
Centre Hospitalier Universitaire De Lille
Département d’hématologie, Rue Michel Polonowski, 59000, Lille
Institut Gustave Roussy
Hématologie, 114 Rue Edouard Vaillant, 94800, Villejuif
Centre Hospitalier Universitaire De Nantes
Département d'hématologie, 1 Place Alexis Ricordeau, 44000, Nantes
Assistance Publique Hopitaux De Paris
Service Immuno-hématologie, 1 Avenue Claude Vellefaux, 75010, Paris
Assistance Publique Hopitaux De Paris
Hémopathies Lymphoïdes, 51 Avenue Du Mal De Lattre De Tassigny, 94010, Creteil Cedex
Assistance Publique Hopitaux De Paris
Département d'hématologie, 149 Rue De Sevres, 75015, Paris
Assistance Publique Hopitaux De Paris
Hématologie Clinique et thérapie cellulaire, 184 Rue Du Faubourg Saint Antoine, 75012, Paris

Greece

2 sites · Ongoing, recruiting
Alexandra Hospital
Oncology and Hematology Unit, Department of Clinical, Vassilissas Sofias Avenue 80, 115 28, Athens
Evaggelismos Hospital
Hematology and Lymphoma Clinic – Bone Marrow Transplantation Unit, Ipsiladou 45-47, 106 76, Athens

Netherlands

2 sites · Authorised, recruitment pending
Universitair Medisch Centrum Groningen
Hematology, Hanzeplein 1, 9713 GZ, Groningen
VUMC Stichting
Hematology, De Boelelaan 1117, 1081 HV, Amsterdam

Spain

13 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Hematology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Clinica Universidad De Navarra
Hematology, Avenue Pio XII 36, 31008, Pamplona
Complexo Hospitalario Universitario De Santiago
Hematology, Calle Choupana Da S/n, 15706, Santiago De Compostela
Hospital Universitario De La Princesa
Hematology, Calle De Diego De Leon 62, 28006, Madrid
Hospital Universitario Ramon Y Cajal
Hematology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Hospital Universitario Hm Sanchinarro
Hematology, Calle Ona 10, 28050, Madrid
Hospital Universitario Marques De Valdecilla
Hematology, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitario 12 De Octubre
Hematology, Bloque D, Avenida De Cordoba Sn, Madrid
Institut Catala D'oncologia
Hematology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitario De Salamanca
Hematology, Paseo De San Vicente 58-182, 37007, Salamanca
Hospital Clinic De Barcelona
Hematology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Quironsalud Madrid
Hematology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Institut Catala D'oncologia
Hematology, Carretera Canyet S/n, 08916, Badalona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2023-03-27 2023-03-27
Greece 2022-11-16 2022-11-16
Spain 2022-08-17 2022-08-17

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-22 Spain Acceptable
2024-06-27
2024-06-27
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-10 Spain Acceptable
2024-11-28
2024-11-28
3 SUBSTANTIAL MODIFICATION SM-2 2025-05-30 Spain Acceptable with conditions
2025-08-28
2025-08-29
4 SUBSTANTIAL MODIFICATION SM-3 2025-12-05 Acceptable with conditions 2026-02-02
5 SUBSTANTIAL MODIFICATION SM-4 2025-12-05 Acceptable with conditions 2026-01-15
6 SUBSEQUENT ADDITION OF MSC APP-6 2025-12-05 Acceptable with conditions
2025-08-28
2026-03-06